INNOVIVA, INC. Accrued Income Taxes, Current
INNOVIVA, INC. (INVA) had Accrued Income Taxes, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedIncomeTaxesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Income Taxes, Current $0.00.
- 2026-03-31: Accrued Income Taxes, Current $0.00.
- 2025-12-31: Accrued Income Taxes, Current $274.00K.
- 2025-03-31: Accrued Income Taxes, Current $1.54M.
| Period end | Accrued Income Taxes, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 |
| 2025-12-31 | $274.00K 10-Q · filed 2026-08-05 |
| 2025-03-31 | $1.54M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-25 |
| 2024-09-30 | $2.62M 10-Q · filed 2024-11-06 |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-06 |
| 2023-09-30 | $154.00K 10-Q · filed 2023-11-01 |
| 2023-06-30 | $154.00K 10-Q · filed 2023-08-02 |
| 2023-03-31 | $154.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $154.00K 10-K/A · filed 2024-03-05 |
| 2022-09-30 | $33.80M 10-Q · filed 2022-11-09 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |